Key Takeaways
- DA Davidson slashed UiPath’s rating to Underperform from Neutral, slicing the price target down to $10.
- Customer resistance to AI pricing models emerged as the primary concern following UiPath’s FUSION conference and Investor Day.
- PATH shares have declined 8% in the past week, trading beneath both the 50-day and 200-day moving averages.
- The Street’s overall sentiment stays neutral with a Hold rating and $15.69 average target price.
- Despite topping Q2 forecasts for revenue and earnings, company insiders offloaded more than $24 million worth of shares in three months.
Automation software provider UiPath (PATH) faces renewed selling pressure following DA Davidson‘s decision Monday to downgrade the stock to Underperform from Neutral. The investment firm simultaneously reduced its price objective to $10, significantly beneath current trading levels.
The automation platform’s shares began trading at $12.23 and have shed 8% throughout the previous week. This decline positions the equity underneath its 50-day moving average of $14.53 and approaching its 200-day average of $12.24.
According to analyst Lucky Schreiner, pricing challenges represent the central catalyst behind the rating cut. These worries surfaced after DA Davidson attended both UiPath’s FUSION conference and subsequent Investor Day presentations.
During these corporate events, UiPath outlined its vertical-focused market approach and introduced pre-built solution packages designed to accelerate customer implementation timelines. Management also emphasized the company’s commitment to deterministic outcomes and expanded deployments when clients integrate orchestration capabilities with automation technologies.
Customer and partner sentiment gathered at the conference proved inconsistent. Resistance to artificial intelligence pricing structures emerged as the most significant obstacle highlighted in DA Davidson’s assessment.
Analyst Community Divided on PATH Outlook
The downgrade doesn’t represent unanimous opinion across the analyst community. Wall Street’s collective rating on PATH sits at Hold, accompanied by a mean price objective of $15.69.
Multiple research firms have recently reduced price objectives while maintaining neutral positions. BMO Capital Markets decreased its forecast to $15 from $18, and UBS trimmed its target to $15 from $19 following UiPath’s decision to withhold preliminary fiscal 2028 revenue guidance.
TD Cowen maintained a $16 price objective alongside a Hold rating, whereas RBC Capital reduced its target to $15 citing execution uncertainties. Truist Securities brought its forecast down to $14, and Bank of America lifted its target to $15 while preserving an Underperform stance.
Among total analyst coverage, four analysts assign PATH a Buy rating, fifteen recommend Hold, and two suggest Sell.
Financial Performance and Insider Transactions
UiPath’s most recent quarterly results, disclosed September 3, surpassed Wall Street projections. The organization reported earnings per share of $0.15, meeting consensus expectations, alongside revenue of $410.26 million compared to the $397.77 million analyst estimate.
Top-line results increased 13.3% compared to the prior-year period. Net profit margin registered at 21.03%, while return on equity measured 9.70%. Wall Street forecasts UiPath will deliver $0.49 in earnings per share for the ongoing fiscal year.
Insider dispositions have accelerated concurrent with the stock’s downturn. Raghavendra Malpani divested 40,464 shares on September 17 at $14.00 per share, generating proceeds of $566,496.
Chief Operating Officer Ashim Gupta offloaded 117,339 shares on September 11 at an average price of $13.85, a deal valued at approximately $1.63 million. This transaction reduced his stake by 5.45%.
Throughout the preceding 90 days, company insiders have disposed of 1.56 million PATH shares totaling $24.7 million in aggregate value. Corporate insiders presently control 22.44% of outstanding equity.
Institutional investment managers possess a more substantial portion of UiPath, controlling 62.5% of shares outstanding. Multiple funds expanded their holdings in recent quarters, including Allworth Financial LP and Corient Private Wealth LLC.
UiPath maintains a market capitalization of $6.37 billion, a price-to-earnings ratio of 18.25, and a beta coefficient of 1.02. The stock’s 52-week trading range extends from $9.20 to $19.84.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
